Claims
- 1. A method for making an antibody comprising the following steps: (a) binding antibody phage from a naïve antibody phage library to a live cancer cell; (b) selecting an antibody phage or antibody which binds selectively to the live cancer cell; and (c) identifying an antigen to which the antibody phage or antibody binds.
- 2. The method of claim 1 further comprising counter-selecting the antibody phage using a live non-cancer cell.
- 3. The method of claim 2 wherein the counter-selecting step is performed prior to step (a).
- 4. The method of claim 2 wherein the mean number of antigen molecules per cancer cell is greater than the mean number of antigen molecules per non-cancer cell.
- 5. The method of claim 4 wherein the mean number of antigen molecules per cancer cell is about two fold to about 1000 fold greater than the mean number of antigen molecules per non-cancer cell.
- 6. The method of claim 4 wherein the mean number of antigen molecules per cancer cell is about five fold to about 100 fold greater than the mean number of antigen molecules per non-cancer cell.
- 7. The method of claim 2 wherein the non-cancer cell is of the same tissue-type as the cancer cell.
- 8. The method of claim 1 wherein the cancer cell is a lung cancer cell.
- 9. The method of claim 1 wherein the antibody phage library comprises from about 109 to about 1015 antibody phage.
- 10. The method of claim 1 further comprising expression cloning the antigen.
- 11. The method of claim 1 wherein the cancer cell is from a cancer cell line.
- 12. The method of claim 2 further comprising comparing binding of the antibody phage or antibody to a cancer cell and a non-cancer cell.
- 13. The method of claim 1 further comprising detaching the cancer cell from a surface to which the cancer cell is adhered using a solution which does not include any protease.
- 14. The method of claim 13 wherein the solution comprises EDTA for detaching the cancer cell.
- 15. A method for identifying an antigen which is differentially expressed on the surface of two or more distinct cell populations, comprising the following steps: (a) binding antibody phage from a naïve antibody phage library to a first cell population; (b) binding the antibody phage to a second cell population which is distinct from the first cell population; (c) selecting an antibody phage or antibody which binds selectively to the first cell population; and (d) identifying an antigen to which the antibody phage or antibody binds.
- 16. The method of claim 15 wherein the first cell population is a cancer cell population and the second cell population is a non-cancer cell population of the same tissue type as the cancer cell population.
- 17. The method of claim 16 wherein the antibody phage from the phage library are counter-selected with the second cell population, prior to being bound by the first cell population.
- 18. An antibody prepared according to the method of claim 1.
- 19. The antibody of claim 18 which is used for in vivo cancer diagnosis or therapy.
- 20. An antibody directed against an antigen, wherein the antigen has been identified according to the method of claim 15.
- 21. An isolated human antibody directed against human decay accelerating factor (DAF) obtainable by the method of claim 1.
- 22. An isolated human antibody directed against human decay accelerating factor (DAF) which has a binding affinity for human DAF of about 10 nM or better.
- 23. The antibody of claim 22 which binds an epitope on DAF bound by an antibody selected from the group consisting of LU30, LU13 and LU20.
- 24. The antibody of claim 22 comprising antigen-binding amino acid residues of an antibody selected from the group consisting of LU30, LU13 and LU20.
- 25. The antibody of claim 22 which is selected from the group consisting of LU30, LU13, LU20, an affinity matured variant of LU30, an affinity matured variant of LU13 and an affinity matured variant of LU20.
- 26. A pharmaceutical composition comprising the antibody of claim 21 and a pharmaceutically acceptable carrier.
- 27. An article of manufacture comprising the pharmaceutical composition of claim 26 and a package insert instructing the user of the composition to treat a patient having, or predisposed to, lung cancer with the composition.
- 28. The article of manufacture of claim 27 wherein the lung cancer is selected from the group consisting of small-cell lung cancer, non-small cell lung cancer, large cell lung carcinoma, lung adenocarcinoma, and squamous cell lung carcinoma.
- 29. A method of treating lung cancer comprising administering a therapeutically effective amount of an antibody directed against decay accelerating factor (DAF) to a patient.
- 30. The method of claim 29 wherein the antibody is a human antibody.
- 31. The method of claim 29 wherein the antibody has a binding affinity for DAF of about 10 nM or better.
- 32. The method of claim 29 wherein the antibody binds an epitope on DAF bound by an antibody selected from the group consisting of LU30, LU13, LU20, 791T36 and SC-1.
- 33. The method of claim 29 wherein the antibody comprises antigen-binding amino acid residues of an antibody selected from the group consisting of LU30, LU13, LU20, 791T36 and SC-1.
- 34. The method of claim 29 wherein the antibody is selected from the group consisting of LU30, LU13, LU20, an affinity matured variant of LU30, an affinity matured variant of LU13 and an affinity matured variant of LU20.
- 35. The method of claim 29 further comprising administering a therapeutically acceptable amount of a second cytotoxic agent, wherein the second cytotoxic agent is selected from the group consisting of navelbine, gemcitabine, a taxoid, carboplatin, cisplatin, etoposide, cyclosphosphamide, mitomycin, vinblastine, an anti-ErbB2 antibody, an anti-angiogenic factor antibody, an anti-mucin antibody, and a second antibody directed against a different epitope on DAF.
- 36. The method of claim 35 wherein therapy with the combination of the antibody and the second cytotoxic agent is synergistic.
Parent Case Info
[0001] This application is a non-provisional application filed under 37 CFR 1.53(b)(1), claiming priority under 35 USC 119(e) to provisional application No. 60/122,262 filed 3/t/99, the contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60122262 |
Mar 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09515825 |
Feb 2000 |
US |
Child |
10447331 |
May 2003 |
US |